Condition: Advanced Extrapulmonary Neuroendocrine Carcinoma · Sponsor: Nanjing Leads Biolabs Co.,Ltd
This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.
This description comes directly from the study's public registry record.
Lin Shen · 010-88121122 · doctorshenlin@sina.cn
Always discuss trial participation with your own doctor first.
| Beijing GoBroad Hospital | Beijing, Beijing Municipality, China | — |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | — |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | — |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | — |
| The First Affiliated Hospital,Sun Yat-sen University | Guangzhou, Guangdong, China | — |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | — |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | — |
| The First Affiliated Hospital of Henan University of Science & Technology | Luoyang, Henan, China | — |
| Henan Cancer Hospital | Zhengzhou, Henan, China | — |
| Shandong Cancer Hospital | Jinan, Shandong, China | — |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | — |
| Shanxi Provincial Cancer Hospital | Taiyuan, Shanxi, China | — |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07720193